Accredited CME: The future of urticaria - advances in CSU research - launched to Medthority.com
A new and interactive CME has launched on Medthority.com, giving healthcare professionals the opportunity to further their understanding of urticaria and the science behind it.
Compriasing videos from leading experts presenting at the Medthority.com-sponsored symposium ‘The future of urticaria – advances in CSU research’ at EAACI 2017 and interspersed with interative quizzes and questions after each bite-size module, medics can test their knowledge and understanding as they progress through the course.
On completion of the CME, HCPs should have an understanding of:
- The continuing unmet needs in CSU
- The progress made in identifying and managing CSU patients
- The latest research in therapy areas beyond CSU that may benefit from our increased pathophysiological understanding.
This CME was supported by an educational grant from Novartis, who were given the opportunity to review the content for medical accuracy only. It consists of 4 modules that include video clips taken from expert presentations interspersed with quiz and evaluation questions. To claim CME credit you must complete all presentations and achieve a score of 70% in the final assessment.
View more information and register for this free CME in the CSU Knowledge Centre on Medthority.com.
Related news and insights
Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has issued a Complete Response Letter (CRL) for the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) in chronic spontaneous urticaria (CSU)
Novartis announced positive top-line results from the Phase III REMIX-1 and REMIX-2 studies evaluating remibrutinib 25 mg b.i.d., a Bruton’s tyrosine kinase (BTK) inhibitor, in patients with chronic spontaneous urticaria (CSU) whose symptoms are inadequately controlled by H1-antihistamines
Regeneron Pharmaceuticals, In and Sanofi announced that the FDA has accepted for review the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) to treat adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) that is not adequately controlled with H1 antihistamine treatment. The target action date for the FDA decision is October 22, 2023.